Nucleic Acid Based Gene Therapy: Critical Driver Shaping the Government And Industry Backing Fueling The Surge In Nucleic Acid-Based Gene Therapy Demand Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Nucleic Acid Based Gene Therapy Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for nucleic acid based gene therapy has experienced robust expansion in the past few years. The market, which was valued at $0.81 billion in 2024, is projected to reach $0.88 billion in 2025, marking an impressive compound annual growth rate (CAGR) of 8.4%. This notable growth during the historical period can be linked to factors such as increased knowledge of human genetics, rising demand for tailored medicine, an extensive pipeline of gene therapy products, increased government backing for gene therapy, genetic disorders, and cancer therapy.

Nucleic Acid Based Gene Therapy Market Size Forecast: What's the Projected Valuation by 2029?
Over the coming years, the market size of nucleic acid-based gene therapy is anticipated to experience a surge. The expected growth trajectory suggests a rise to $1.3 billion by 2029, with a compound annual growth rate (CAGR) of 10.3%. The predicted growth during this forecast period is due to various factors such as increasing indications, heightened patient advocacy and awareness, burgeoning investments in gene therapy R&D, expansion of gene therapy applications, and treatment of rare diseases. As we move into this forecast period, we foresee major trends like ex vivo gene editing, evolution in in vivo gene editing, combination therapies, targeted delivery systems, gene editing for tackling rare diseases, and non-viral vectors.

View the full report here:
https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

What Are the Drivers Transforming the Nucleic Acid Based Gene Therapy Market?
The increase in financial backing from both the government and corporate entities is expected to propel the need for gene therapy based on nucleic acid. Nucleic acid treatments serve as analogs to naturally existing acids or proteins that determine genetic expression. Conventional therapies do not offer any solution for managing diseases like cystic fibrosis, hemophilia, sickle cell anemia, thalassemia, and diabetes. The foundation of these drug categories is based on genetic profiling and molecular target identification. Nucleic acid medications present a higher potential in treating these illnesses, since they address the genetic origin of diseases and offer a lasting cure. The escalating financial aid from the government and businesses involved in the gene therapy market is likely to drive the demand for gene therapy based on nucleic acid. For example, the National Institute of Health (NIH) declared in August 2022 that it would invest $34 million annually for the next five years to advance HIV treatment research. This governmental backing for gene therapies is expected to facilitate the expansion of the market for gene therapy based on nucleic acid.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp

Which Segments in the Nucleic Acid Based Gene Therapy Market Offer the Most Profit Potential?
The nucleic acid based gene therapy market covered in this report is segmented -

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies
2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases
3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:
1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)
2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies
3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)
4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs
5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes
6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers
7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2820&type=smp

Which Firms Dominate the Nucleic Acid Based Gene Therapy Market by Market Share and Revenue in 2025?
Major companies operating in the nucleic acid based gene therapy market include Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., logy Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

Which Regions Offer the Highest Growth Potential in the Nucleic Acid Based Gene Therapy Market?
North America was the largest region in the nucleic acid-based gene therapy market in 2024. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2820

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.